Previous close | 0.8000 |
Open | 0.8000 |
Bid | 0.8000 |
Ask | 1.2000 |
Strike | 12.50 |
Expiry date | 2024-10-18 |
Day's range | 0.8000 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | 192 |
SAN FRANCISCO, May 21, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy, June 5-8. The Company plans to host an investor conference call to discuss the new SOLSTICE data
Shareholders in Vir Biotechnology, Inc. ( NASDAQ:VIR ) may be thrilled to learn that the analysts have just delivered a...
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.